RA Capital Management’s Tyra Biosciences TYRA Stock Holding History

RA Capital Management’s Portfolio TYRA Stock Details TYRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$390M	Hold	12,198,625	–	–	3.39%	6
2026 Q1	$467M	Hold	12,198,625	–	–	4.95%	4
2025 Q4	$321M	Hold	12,198,625	–	–	3.29%	8
2025 Q3	$171M	Hold	12,198,625	–	–	2.1%	13
2025 Q2	$117M	Buy	12,198,625 +1,561,335	+15%	+$14.8M	1.97%	15
2025 Q1	$98.9M	Hold	10,637,290	–	–	1.65%	15
2024 Q4	$148M	Buy	10,637,290 +220,681	+2%	+$4M	1.97%	13
2024 Q3	$245M	Hold	10,416,609	–	–	2.82%	7
2024 Q2	$167M	Hold	10,416,609	–	–	2.2%	13
2024 Q1	$171M	Buy	10,416,609 +3,180,155	+44%	+$52.2M	2.17%	10
2023 Q4	$100M	Hold	7,236,454	–	–	1.57%	15
2023 Q3	$99.6M	Hold	7,236,454	–	–	1.96%	11
2023 Q2	$123M	Hold	7,236,454	–	–	2.33%	10
2023 Q1	$116M	Hold	7,236,454	–	–	2.63%	11
2022 Q4	$55M	Hold	7,236,454	–	–	1.12%	27
2022 Q3	$63.6M	Hold	7,236,454	–	–	1.36%	24
2022 Q2	$51.7M	Hold	7,236,454	–	–	1.38%	23
2022 Q1	$77.4M	Hold	7,236,454	–	–	1.69%	14
2021 Q4	$102M	Hold	7,236,454	–	–	1.8%	13
2021 Q3	$127M	Buy	+7,236,454	New	+$138M	1.76%	18

Other funds holding TYRA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

APMC

Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

RA Capital Management's TYRA Position: Q2 2026 in Review

RA Capital Management held its Tyra Biosciences (TYRA) position steady in Q2 2026 at 12,198,625 shares worth $390M. The position accounts for 3.39% of the portfolio, ranked #6.

RA Capital Management first reported a position in TYRA in Q3 2021 and has held it in 20 quarters since. The position peaked at $467M in Q1 2026. 169 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

RA Capital Management held 12,198,625 shares of Tyra Biosciences worth $390M as of Q2 2026.
RA Capital Management left its Tyra Biosciences share count unchanged in Q2 2026.
Tyra Biosciences made up 3.39% of RA Capital Management's portfolio in Q2 2026, its #6 holding.
RA Capital Management first reported a position in Tyra Biosciences in Q3 2021 and has held it in 20 quarters since.
RA Capital Management's Tyra Biosciences position peaked at $467M in Q1 2026.
169 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.